Diabetes is the fourth leading cause of death worldwide. Remains a global health problem, with the number projected to rise from 285 million in 2010 to nearly 400 million cases by the year 2030.
Plasma Protein supplementation helps prevent the death of pancreatic beta cells in diabetes
Although drugs have been developed to control diabetes there is no treatment that can cure the disease. In the long term, the disease can cause complications affecting the eyes, heart, kidneys and nerves.
“Supplementation with a plasma protein S, manufactured by the human body, can be key in preventing death of beta cells of the pancreas in diabetes. “
Diabetes has two main forms: type 1, in which the body does not produce insulin and type 2, in which the body has too little insulin or can not use insulin properly. The cause of reduced insulin in the body that is common to both types of diabetes is the death of pancreatic cells important beta-: cells that produce and regulate insulin in the body.
Isaac Cann, professor of zoology, microbiology at the University of Illinois, and colleagues at the School of Medicine (Japan) Mie University have discovered that a protein produced by the human body can be key in preventing cell death in diabetes.
A research collaboration between the U of I and Mie University Faculty and the Faculty of Medicine in Japan, shows evidence that supplementation of the S protein, a plasma protein that is reduced in people with diabetes, can help minimize the effects disease by suppressing cell death of beta cells.
“A major problem of diabetes is the death of beta cells, of course, produce insulin. Type 1 diabetes is primarily genetic, while type 2 is basically related to lifestyle, but progression diabetes is the same, “Cann explains. “We know that in each case there apoptosis (death) of these cells that produce insulin. So this study actually looking for ways to prevent this cell death. Regardless of the type of diabetes, if the S protein is actually able to prevent the death of cells that produce insulin, then of course it will help in both cases.
“And so by finding that this protein, which is actually made by humans, abolishes the death of these cells is really an important finding. Perhaps supplementation of this particular protein can help alleviate progression the illness.”
Protein S is an anticoagulant factor regulating inflammation and cell destruction or cell death. Little has been known about the effect of protein S on diabetes and related complications.
Cann et al established a study to compare the development of diabetes in mice that were overexpressing human S (transgenic) protein, or protein S were administered after developing diabetes.
The researchers observed a significant inhibition of the death of beta cells through improvements observed in the levels of blood glucose, glucose tolerance, insulin sensitivity and less severe kidney damage in the S protein mice and mice they had been treated with S.
Because the level of protein S in circulation is reduced in people with diabetes, researchers were encouraged to see that the S protein supplements had an impact.
“Our bodies are very complex Unless there is another protein that degrades the S protein -. Which in this case, this treatment will not work – we thought perhaps increasing or administration of the S protein could work No saw degradation. of the S protein, at least in a mouse. If administered directly or increase the level, looks good effect. so maybe if given to humans, it will not be degraded and will prevent the death of cells that make insulin, “says Cann.
Esteban Gabazza, immunologist and professor at Mie University, explains that the death of cells that are essential for the function of organs is the cause of many diseases, one of which is diabetes. “Death structural kidney cells also cause kidney disease in people with diabetes. Therefore, based on this experimental finding, it is possible that supplementation of protein S can prevent not only the progression of diabetes, but also its kidney complications related.
“Because the prognosis of diabetic patients is much worse than the general healthy population, the clinical application of this new discovery will definitely change the life expectancy of many people who suffer from this disease,” says Gabazza.
Although Cann says it could take some time before a treatment could be available, adds that the study provides enough evidence to suggest that researchers should go ahead with the S.
Ultimately, Cann says about finding a treatment that can be offered before decreasing the complications of diabetes.
“Basically, when you have diabetes, your body is malfunctioning. The balance throughout your physiology is thrown out of control. If we are able to stop the problem from the early stages of progression, we can avoid the effects downstream,” he says .
Cann continue to work with Gabazza (corresponding author) and his colleagues at Mie University to better understand diabetes.
“We believe this is only a first step for these collaborations. We will also bring in our knowledge of the microbiome to work in diabetes, and maybe find some new solutions,” says Cann. “Many laboratories are working on this, but this is a very important contribution. Hopefully this is a concept that others will go out and test.”
This article was originally published on medindia.net
Posted in: health news